PCSK9 inhibitors: emerging treatment to lower cholesterol?

Gencer, B; Rodondi, Nicolas; Mach, F (2014). PCSK9 inhibitors: emerging treatment to lower cholesterol? Revue médicale suisse, 10(420), pp. 539-542. Médecine & Hygiène

Full text not available from this repository. (Request a copy)

The achievement rate of recommended low-density lipoprotein cholesterol (LDL-C) targets of < 1.8 mmol/l for secondary prevention in very high risk patients is difficult. Observational studies reported that loss of function mutation of the PCS9 was associated with LDL-C decrease level and reduction of cardiovascular events. Monoclonal antibodies to PCSK9 (REGN727 and AMG 145, PSCK9 inhibitors) have been tested in clinical studies of phase I and II and showed LDL-C level reduction of 60-70% compared to placebo. This approach appears safe and well-tolerated. The PCSK9 inhibitors are now tested in large phase III clinical studies to assess the long-term safety and efficacy of this new promising approach.

Item Type:	Journal Article (Further Contribution)
Division/Institute:	04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine
UniBE Contributor:	Rodondi, Nicolas
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0025-6749
Publisher:	Médecine & Hygiène
Language:	French
Submitter:	Patricia Rajaonina
Date Deposited:	07 Apr 2015 12:00
Last Modified:	05 Dec 2022 14:44
PubMed ID:	24701672
URI:	https://boris.unibe.ch/id/eprint/66231